Genetic testing for depression drugs shows delayed payoff

Clinical Takeaway: Pharmacogenetic testing for SSRIs may improve longer-term depression remission, but the benefit is not immediate and remains too early to drive routine practice.

About one in three patients with depression do not respond adequately to a first SSRI, and prior trials of pharmacogenetic testing have produced mixed results, often using proprietary algorithms that are hard to compare across studies. This trial evaluated whether testing for two well-validated genes that affect SSRI metabolism, paired with public clinical guidelines, would improve outcomes in routine care.

The findings split by follow-up window. Three-month outcomes showed no benefit from genotype-guided prescribing, but six-month remission rates were significantly higher — suggesting the intervention works on a slower clock than the trial was designed to detect.

Among patients with an actionable metabolizer phenotype, depression scores at three months improved similarly with genotype-guided prescribing and usual care. Patient Health Questionnaire-8 scores and medication side-effect burden showed no difference between groups at three months either.

The picture changed at six months. Remission rates were significantly higher with genotype-guided prescribing on both depression measures: 48.3% versus 39.4% on the PROMIS scale, and 29.9% versus 21.0% on the PHQ-8. A prespecified time-trend analysis showed scores diverging in favor of genotype guidance through month six.

Patients in the genotype-guided group were also more likely to be on a medication and dose matched to their metabolizer phenotype at three months (84.5% versus 74.3%), suggesting the prescribing changes did happen but they simply took longer to translate into clinical benefit.

The trial randomized 1,460 patients across nine US health systems between 2021 and 2024, including 221 children. Patients had a depression diagnosis with at least three months of symptoms and were starting or adjusting SSRI therapy. About 47% had an actionable CYP2D6 or CYP2C19 phenotype — a poor, intermediate, rapid, or ultrarapid metabolizer status for which clinical guidelines recommend a different drug or dose.

Phenoconversion from CYP2D6-inhibiting medications was accounted for, which raised the prevalence of the poor metabolizer phenotype from about 6% to 20%. The trial used publicly available Clinical Pharmacogenetics Implementation Consortium guidelines rather than a commercial algorithm.

The pragmatic design did not collect detailed data on when SSRI changes occurred, so part of the three-month null may reflect delays in acting on test results. About 15% of patients in the genotype-guided group with actionable phenotypes were not on concordant therapy at three months, which may have diluted the intervention effect.

For practice, the findings will not settle the long-running debate over pharmacogenetic testing in depression. The trial restricted analysis to patients with actionable phenotypes, which was fewer than half of those tested, and still found significant effects on only some secondary outcomes, so result should be read cautiously. But the longer-term remission signal, consistent across two scales and aligned with prior trials using commercial algorithms, suggests the benefit may build over time rather than appear immediately after a prescription change.

"These findings suggest a possible longer-term clinical benefit and indicate that future studies should focus on the durability and long-term impact of genotype-guided prescribing in the management of depressive symptoms," the authors conclude.

Source: Blake KV. JAMA Netw Open. 2026 May 6. Genotype-Guided Antidepressant Prescribing for Patients With Depression